Repeated studies have shown that in postmenopausal women receiving estrogen, coronary artery disease is found to be much less common than those who refuse to receive it.
After menopause in the female body, the allocation of estrogen to the ovaries gradually decreases. This cycle can take several years.
Along with this there is an increase in the content of so-called bad cholesterol and a decrease in good cholesterol in the blood. It is these changes in lipid metabolism, which is commonly believed to be in official medicine, is the main cause of an increased risk of coronary artery disease.
As a rule, women who have undergone a surgical ovarian or menopause surgery that occurred at a fairly early age are also at the risk of coronary artery disease.
The resistance of young women to developing coronary heart disease (CHD) compared with men of the same age is explained by the fact that women have a favorable lipid profile that greatly depends on their hormonal status.
After the onset of menopause, the risk of developing this disease is rising sharply, so women should also be included in the initial program for the prevention of coronary artery disease.
Hormonal prophylaxis of ischemic heart disease
Treatment of coronary artery disease in women for a long time was accompanied initially by hormonal treatment with estrogen, which greatly increased the positive cholesterol and reduced the level of bad cholesterol.
For a long time, physicians have assumed, and this opinion remains to this day that estrogen is a qualitative and effective protection of women from the development of coronary artery disease, stroke, and dementia.
Repeated studies have shown that in postmenopausal women receiving estrogen, coronary artery disease is found to be much less common than those who categorically refused to receive it. Many of these studies were conducted in a simple form of observation, where each woman could choose independently, use estrogen or not.
Women who decided to take estrogen in the post-menopausal period looked much healthier and had a very low risk of developing heart attacks compared to those who did not use estrogen.
Also, the study of the health of women with coronary artery disease was conducted on the effectiveness of therapy, when the daily estrogen supplement was supplemented with progestin in heart attacks. With the constant use of estrogen (progestin), the reduction in heart attacks in women was not observed.
Studies have also shown that many women who use estrogens began to develop thrombi in the veins, and there were diseases of the gall bladder.
Thrombi that is formed in the veins is especially dangerous: they can get into the lungs through the bloodstream, cause pulmonary embolism and cause a sudden death.
However, in healthy women who do not suffer from cardiovascular disease, the development of gallbladder diseases and the formation of blood clots, which occurs on the background of estrogen receptivity, was diagnosed in a minimal amount.
Based on these studies, it has been shown that the use of estrogen in women after menopause is ineffective in the prevention of coronary artery disease, heart attacks, if the disease data are already existing or have taken place before.